Correlates of HIV-1 viral suppression in a cohort of HIV-positive drug users receiving antiretroviral therapy in Hanoi, Vietnam

International Journal of STD and AIDS

Volumn 20, Issue 6, 2009, Pages 418-422

  Jordan, M R ^a   La, H ^a   Nguyen, H D ^b   Sheehan, H ^a   Lien, T T M ^b   Duong, D V ^b   Hellinger, J ^a   Wanke, C ^a   Tang, A M ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b National Institute for Infectious and Tropical Diseases   (Viet Nam)

Author keywords

Adherence; Antiretroviral therapy; HIV; Substance abuse; Vietnam

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG USE; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; TOBACCO; TUBERCULOSIS; VIET NAM;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; DRUG USERS; HIV INFECTIONS; HIV-1; HUMANS; MALE; PATIENT COMPLIANCE; REVERSE TRANSCRIPTASE INHIBITORS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; VIETNAM; VIRAL LOAD; YOUNG ADULT;

EID: 67549135755     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2008.008389     Document Type: Article

References (31)

1. UNAIDS, 2005. HIV/AIDS estimates and projections 2005-2010. http:// www.unaids.org.un/resource/topic/epidemiology/e%20&%20p-english- final.pdf. (last accessed 30-09-2008)
2. Nguyen VT, Scannapieco M. Drug abuse in Vietnam: a critical review of the literature and implications for future research. Addiction 2008;103:535-543
3. UNAIDS. 2004 Report on the Global AIDS Epidemic. Geneva: UNAIDS, 2004
4. WHO/UNAIDS. WHO/UNAIDS report on global AIDS epidemic. Geneva 2007
5. Vietnamese Ministry of Health. The National Gguidelines for Diagnosis and Treatment of HIV/AIDS. 2000
6. Vietnamese Ministry of Health. Guidelines for Diagnosis and Treatment of HIV/AIDS. 2005
7. Lee PK, Kieffer TL, Siliciano RF, et al. HIV-1 viral load blips are of limited clinical significance. J Antimicrob Chemother 2006;57:803-805
8. National Institute on Alcohol Abuse and Alcoholism. The Physician's Guide to Helping Patients with Alcohol Problems. Washington, DC: National Institutes of Health, 1995
9. Giordano TP, Guzman D, Clark R, et al. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials 2004;5:74-79 (Pubitemid 38697081)
10. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568-2577 (Pubitemid 33096808)
11. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360:119-129 (Pubitemid 34786200)
12. Wood E, Montaner JS, Yip B, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ 2003;169:656-661 (Pubitemid 37266973)
13. Koenig SP, Leandre F, Farmer PE. Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience. AIDS 2004; 18(Suppl 3):S21-5 (Pubitemid 39037455)
14. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004;18:887-895 (Pubitemid 38553709)
15. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002;360:34-40 (Pubitemid 34756490)
16. Samet JH, Walley AY, Bridden C. Illicit drugs, alcohol, and addiction in human immunodeficiency virus. Panminerva Med 2007;49:67-77
17. Palepu A, Tyndall MW, Joy R, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend 2006;84:188-194 (Pubitemid 44119095)
18. De Luca A, Bugarini R, Lepri AC, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002;162:2125-2132 (Pubitemid 35168221)
19. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008;300:530-539
20. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30 (Pubitemid 30432540)
21. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14:357-366
22. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 2001;33:1417-1423 (Pubitemid 32955198)
23. Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999;37:846-857
24. Gross R, Zhang Y, Grossberg R. Medication refill logistics and refill adherence in HIV. Pharmacoepidemiol Drug Saf 2005;14:789-793 (Pubitemid 41684471)
25. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to non-nucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007;146:564-573 (Pubitemid 351650537)
26. Howard AA, Arnsten JH, Lo Y, et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS 2002;16:2175-2182 (Pubitemid 35387272)
27. Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy 2007;18:262-270 (Pubitemid 47126278)
28. La H, Skinner S, Tang A. Polysubstance use and adherence to antiretroviral therapy among HIV-positive drug users in three US cities. Third International Conference on HIV Treatment Adherence. Jersey City, NJ; 2008
29. Hicks PL, Mulvey KP, Chander G, et al. The impact of illicit drug use and substance abuse treatment on adherence to HAART. AIDS Care 2007;19:1134-1140 (Pubitemid 350223192)
30. Bertagnolio S, Sutherland D. WHO approach to track HIV drug resistance emergence and transmission in countries scaling up HIV treatment. AIDS 2005;19:1329-1330 (Pubitemid 41224905)
31. Jordan MR, Bennett D, Bertagnolio S, et al.World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 2008;13(Suppl):215-223 (Pubitemid 352019086)